To ask the Secretary of State for Health pursuant to the answer of 23 November 2010, Official Report, column 251W, on Hemofil T: clinical trials, what consideration his Department has given to obtaining information on the proportion of patients on the Hemofil T trial that were mild, moderate or severe...

To ask the Secretary of State for Health pursuant to the answer of 23 November 2010, Official Report, column 251W, on Hemofil T: clinical trials, what consideration his Department has given to obtaining information on the proportion of patients on the Hemofil T trial that were mild, moderate or severe...

To ask the Secretary of State for Health what the age was of the youngest person on the Hemofil T trial in the early 1980s.

To ask the Secretary of State for Health what the age was of the youngest person on the Hemofil T trial in the early 1980s.

To ask the Secretary of State for Health how many previously untreated patients were used in trials of the Factor VIII concentrate Hemofil T in the early 1980s.

To ask the Secretary of State for Health how many previously untreated patients were used in trials of the Factor VIII concentrate Hemofil T in the early 1980s.

To ask the Secretary of State for Health what proportion of patients on the Hemofil T trial was classified as (a) mild, (b) moderate and (c) severe haemophiliac.

To ask the Secretary of State for Health what proportion of patients on the Hemofil T trial was classified as (a) mild, (b) moderate and (c) severe haemophiliac.

To ask the Secretary of State for Health for what period of time her Department plans to fund recombinant Factor VIII for use by haemophiliacs in the UK.

To ask the Secretary of State for Health for what period of time her Department plans to fund recombinant Factor VIII for use by haemophiliacs in the UK.

To ask the Secretary of State for Health, how many suppliers of recombinant clotting factor for haemophilia patients there are in the UK. - Includes figures.

To ask the Secretary of State for Health, how many suppliers of recombinant clotting factor for haemophilia patients there are in the UK. - Includes figures.

To ask the Secretary of State for Health, what factors are preventing targets for the required amount of recombinant clotting factor for haemophilia patients being met; what the budget is for 2003-04 to provide recombinant clotting factor for haemophilia patients. - Includes figures.

To ask the Secretary of State for Health, what factors are preventing targets for the required amount of recombinant clotting factor for haemophilia patients being met; what the budget is for 2003-04 to provide recombinant clotting factor for haemophilia patients. - Includes figures.

To ask Mr Chancellor of the Exchequer, pursuant to his Answer of 7 April 2003, 403 c26W, on blood products, what representations the UK Government has made to the European Commission about extending the VAT exemption; and whether it is the policy of the Government to support change.

To ask Mr Chancellor of the Exchequer, pursuant to his Answer of 7 April 2003, 403 c26W, on blood products, what representations the UK Government has made to the European Commission about extending the VAT exemption; and whether it is the policy of the Government to support change.

To ask the Secretary of State for Health, what the underspend was on last year's budget for recombinant clotting factor for haemophilia patients in West Gloucestershire Primary Care Trust.

To ask the Secretary of State for Health, what the underspend was on last year's budget for recombinant clotting factor for haemophilia patients in West Gloucestershire Primary Care Trust.

To ask Mr Chancellor of the Exchequer, if he will make it his policy to bring the level of VAT on recombinant blood products in line with that in other European countries.

To ask Mr Chancellor of the Exchequer, if he will make it his policy to bring the level of VAT on recombinant blood products in line with that in other European countries.

To ask the Secretary of State for Health, if he will make a statement on the charging mechanisms for providing recombinant factor VIII to haemophiliacs under the age of 20 but over the age of 16.

To ask the Secretary of State for Health, if he will make a statement on the charging mechanisms for providing recombinant factor VIII to haemophiliacs under the age of 20 but over the age of 16.

To ask the Secretary of State for Health, what figures he has collated on the price paid in (a) the UK, (b) each other EU country, (c) the USA and (d) Japan for rcFVIII for the treatment of haemophiliacs. - Inc figures.

To ask the Secretary of State for Health, what figures he has collated on the price paid in (a) the UK, (b) each other EU country, (c) the USA and (d) Japan for rcFVIII for the treatment of haemophiliacs. - Inc figures.

To ask the Secretary of State for Health, how many overseas patients in the UK (a) under and (b) over 16 years of age are being treated with rcFVIII products. - The information requested is not collected centrally.

To ask the Secretary of State for Health, how many overseas patients in the UK (a) under and (b) over 16 years of age are being treated with rcFVIII products. - The information requested is not collected centrally.

To ask the Secretary of State for Health, when recombinant genetically engineered haemophiliac treatment will be available to all patients in England. - (Holding answer 26 June 2001).

To ask the Secretary of State for Health, when recombinant genetically engineered haemophiliac treatment will be available to all patients in England. - (Holding answer 26 June 2001).

To ask the Secretary of State for Health, what plans he has to obtain supplies of synthetic factor 8 for the treatment of haemophilia in the United Kingdom whilst the Bayer plant in the USA is closed.

To ask the Secretary of State for Health, what plans he has to obtain supplies of synthetic factor 8 for the treatment of haemophilia in the United Kingdom whilst the Bayer plant in the USA is closed.

To ask the Secretary of State for Health, what advice he is giving haemophilia patients regarding the safety of human plasma-derived factor 8 with respect to (a) hepatitis A, B, C, (b) Aids and (c) CJD.

To ask the Secretary of State for Health, what advice he is giving haemophilia patients regarding the safety of human plasma-derived factor 8 with respect to (a) hepatitis A, B, C, (b) Aids and (c) CJD.

To ask the Secretary of State for Health, if value-added tax is chargeable on (a) supplies of recombinant factor VIII for the treatment of haemophiliacs and (b) supplies of conventionally produced factor VIII; what representations he has made to HM Treasury in respect of charging VAT on these substances; on...

To ask the Secretary of State for Health, if value-added tax is chargeable on (a) supplies of recombinant factor VIII for the treatment of haemophiliacs and (b) supplies of conventionally produced factor VIII; what representations he has made to HM Treasury in respect of charging VAT on these substances; on...

To ask the Secretary of State for Health, if he will make it his policy to grant special payments to haemophilia sufferers who have contracted the hepatitus C infection as a result of treatment with the human derived blood product factor 8.

To ask the Secretary of State for Health, if he will make it his policy to grant special payments to haemophilia sufferers who have contracted the hepatitus C infection as a result of treatment with the human derived blood product factor 8.

To ask the Secretary of State for Health, what plans he has to extend the provision of recombinant factor 8 to treat haemophilia patients of all ages.

To ask the Secretary of State for Health, what plans he has to extend the provision of recombinant factor 8 to treat haemophilia patients of all ages.

To ask the Secretary of State for Health, when the Government intends to make Recombinant Factor 8 available to all haemophiliacs in England. - (Holding answer 12 March 2001).

To ask the Secretary of State for Health, when the Government intends to make Recombinant Factor 8 available to all haemophiliacs in England. - (Holding answer 12 March 2001).